SEC 13F Intelligence

Rock Springs Capital Management LP / RARE

Rock Springs Capital Management LP’s Ultragenyx Pharmaceutical In Position

Does Rock Springs Capital Management LP own Ultragenyx Pharmaceutical In (RARE)? Yes — 1.22M shares worth $26M (+1.50% of its 13F portfolio) as of Q1 2026, down from 1.27M shares the prior filed quarter.

Position Value
$26M
Q1 2026
Shares
1.22M
% of Portfolio
+1.50%
Quarters Held
30
currently held

Position History RARE

Reported value by quarter
Q4 ’18: $18MQ4 ’18Q1 ’19: $40MQ2 ’19: $37MQ3 ’19: $26MQ4 ’19: $30MQ4 ’19Q1 ’20: $33MQ2 ’20: $51MQ3 ’20: $47MQ4 ’20: $78MQ4 ’20Q1 ’21: $51MQ2 ’21: $44MQ3 ’21: $72MQ4 ’21: $74MQ4 ’21Q1 ’22: $75MQ2 ’22: $65MQ3 ’22: $49MQ4 ’22: $60MQ4 ’22Q1 ’23: $54MQ2 ’23: $64MQ3 ’23: $53MQ4 ’23: $84MQ4 ’23Q1 ’24: $83MQ2 ’24: $79MQ3 ’24: $110MQ4 ’24: $73MQ4 ’24Q1 ’25: $50MQ2 ’25: $51MQ3 ’25: $37MQ4 ’25: $29MQ4 ’25Q1 ’26: $26Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.22M$26M+1.50%
Q4 20251.27M$29M+1.49%
Q3 20251.25M$37M+2.19%
Q2 20251.39M$51M+3.15%
Q1 20251.39M$50M+2.89%
Q4 20241.74M$73M+2.79%
Q3 20241.98M$110M+3.58%
Q2 20241.92M$79M+2.38%
Q1 20241.77M$83M+2.10%
Q4 20231.75M$84M+2.06%
Q3 20231.48M$53M+1.41%
Q2 20231.38M$64M+1.52%
Q1 20231.34M$54M+1.28%
Q4 20221.29M$60M+1.44%
Q3 20221.19M$49M+1.27%
Q2 20221.09M$65M+1.90%
Q1 20221.03M$75M+1.88%
Q4 2021883.9K$74M+1.72%
Q3 2021801.1K$72M+1.52%
Q2 2021465.0K$44M+0.88%
Q1 2021450.0K$51M+1.12%
Q4 2020566.5K$78M+1.66%
Q3 2020576.8K$47M+1.20%
Q2 2020646.8K$51M+1.39%
Q1 2020747.8K$33M+1.37%
Q4 2019700.0K$30M+0.94%
Q3 2019608.0K$26M+1.04%
Q2 2019580.0K$37M+1.33%
Q1 2019580.0K$40M+1.55%
Q4 2018425.0K$18M+0.87%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rock Springs Capital Management LP’s full portfolio or all institutional holders of RARE.